Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...

That’s where GlucoBoost GLP-1 Booster comes into play. This innovative supplement has garnered attention for its natural approach to weight loss, appealing to those who prefer avoiding synthetic ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class ...

Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 25, 2024 (HealthDay News) -- As the popularity of GLP-1 meds like Wegovy and ...

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...

A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond ...

These findings are part of Prime's ongoing GLP-1 research, including its most recent study, which showed 85% of individuals taking GLP-1 drugs for weight loss no longer took the drug after two years.

If employees are asking about GLP-1 coverage — in pursuit of general weight loss, not just to treat diabetes — HR may need a plan. At a recent Digital Health New York session titled “The ...

An increasing number of states are considering adding coverage for GLP-1 weight loss medications for their Medicaid enrollees. Eli Lilly's (NYSE:LLY) Zepbound (tirzepatide) and Novo Nordisk's (NVO ...

In teens with a diagnosis of obesity, glucagon-like peptide-1 (GLP-1) receptor agonists may lower the risk of suicidal ideation or attempts, a retrospective cohort study suggests. Compared with those ...